Johnson & Johnson (NYSE:JNJ) Shares Sold by Colonial Trust Advisors

Colonial Trust Advisors lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 124,529 shares of the company's stock after selling 3,845 shares during the quarter. Johnson & Johnson makes up about 1.6% of Colonial Trust Advisors' portfolio, making the stock its 15th biggest holding. Colonial Trust Advisors' holdings in Johnson & Johnson were worth $18,009,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of JNJ. IFS Advisors LLC grew its position in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth $29,000. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $32,000. Finally, Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $33,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on JNJ. Bank of America cut their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Morgan Stanley boosted their price objective on Johnson & Johnson from $163.00 to $164.00 and gave the company an "equal weight" rating in a report on Wednesday, April 9th. Wells Fargo & Company lowered their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Finally, Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $171.50.

Johnson & Johnson Stock Up 1.2 %

JNJ stock traded up $1.82 during trading on Monday, hitting $153.55. 4,211,649 shares of the company's stock were exchanged, compared to its average volume of 7,939,132. The business has a 50-day moving average price of $159.40 and a two-hundred day moving average price of $155.17. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $370.03 billion, a price-to-earnings ratio of 23.09, a PEG ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.